Objective: To analyze the effect of human umbilical cord mesenchymal stem cell adjuvant therapy on liver function and fibrosis indicators as well as the degree of inflammation in patients with hepatitis B cirrhosis. Methods: A total of 80 cases with hepatitis B cirrhosis in our hospital from August 2012 to November 2014 were included for study. According to different treatment methods, all included patients were divided into observation group and control group by half. Control group received conventional treatment, observation group received human umbilical cord mesenchymal stem cell adjuvant therapy, and then differences in the levels of liver function indicators, liver fibrosis indicators, inflammation-related indicators and illness-related indicators were compared between two groups. Results: Serum ALB, GLB and A/G values of observation group after treatment were higher than those of control group, and α2-M, TB, APO-A1 and GGT values were lower than those of control group (P<0.05); serum HA, LN, CIV, PⅢNP and PLD values of observation group after treatment were lower than those of control group (P<0.05); serum TGF-β1, PCT, WBC and SIL-2R levels of observation group after treatment were lower than those of control group (P<0.05); serum FT3 and ADP values of observation group after treatment were higher than those of control group, and NO, EGF, ADM and IR values were lower than those of control group (P<0.05). Conclusions: Human umbilical cord mesenchymal stem cell adjuvant therapy for patients with hepatitis B cirrhosis can optimize liver function and inhibit disease progression, and it has active clinical significance.